Section 852 IAC 1-16-4.1 - Standards for approval for optometric legend drug continuing education hoursAuthority: IC 25-24-1-1
Affected: IC 25-24-1-14.1
Sec. 4.1.
(a) The board will approve a course for optometric legend drug continuing education if it determines that the course will make a significant contribution to the professional competency of optometrists who enroll.(b) In determining if a course meets the requirements of this section, the board will consider whether the following requirements are met:(1) The course has substantial content.(2) The course content directly relates to ocular pharmacology or ocular therapeutics.(3) Each faculty member or speaker who has teaching responsibility in the course is qualified by academic work or practical experience to teach the assigned subject.(4) The physical setting for the course is suitable.(5) High quality materials, including notes and outlines, are available to all optometrists in either print or electronic format.(6) The course is of sufficient length to provide a substantial educational experience.(7) Appropriate educational methodology is used, including, but not limited to, the following: (A) Prepared library packages.(B) Courses of programmed instruction.(C) Active participation and demonstration.(D) Audio-visual materials.(8) An adequate number of faculty members or speakers are provided for the course. If audio-visual media are used as teaching materials, live presentations or discussion leaders must accompany the replaying of the media.(c) Courses that are approved by COPE in the areas of ocular pharmacology or ocular therapeutics are acceptable and no approval by the board is required. Automatic approval of COPE approved courses will cease immediately upon notice from COPE that approval of the course has been discontinued for any reason.(d) Courses approved by COPE in the following areas are automatically approved for optometric legend drug continuing education:(2) Perioperative management of ophthalmic surgery (PO).(3) Refractive surgery management (RS).(4) Treatment and management of ocular disease: anterior segment (AS).(5) Treatment and management of ocular disease: posterior segment (PS).(7) Systemic and ocular disease (SD).(8) Oral pharmaceutical (OP).(9) Other COPE courses approved by the board.Indiana Optometry Board; 852 IAC 1-16-4.1; filed Aug 30, 2012, 2:03 p.m.: 20120926-IR-852120164FRAReadopted filed 11/29/2018, 10:35 a.m.: 20181226-IR-852180403RFAReadopted filed 1/2/2024, 3:48 p.m.: 20240131-IR-852230760RFA